Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer

Martin Ries*, Fadi Khreish, Guy Berchem, Samer Ezziddin

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.

Original languageEnglish
Pages (from-to)730-731
Number of pages2
JournalClinical Nuclear Medicine
Volume44
Issue number9
DOIs
Publication statusPublished - 1 Sep 2019

Keywords

  • Cancer
  • Nephropathy
  • Nephrotoxicity
  • PRLT
  • Prostate
  • PSMA
  • Radioligand
  • Renal function

Fingerprint

Dive into the research topics of 'Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer'. Together they form a unique fingerprint.

Cite this